Landry Robert E's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Oct 18, 2022
- Accession no.
- 0001883850-22-000082
- Filed
- Oct 18, 2022
- Trade date
- Oct 14-17, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $264.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Landry Robert ECIK 0001585160 | Officer (EVP Finance CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 14, 2022 | Common Stock | MOption exerciseAcquired | +1,500 | $381.92 | +$572,880 | 30,244 | Direct | |
| Oct 14, 2022 | Common Stock | FTax withholdingDisposed | −1,142 | $743.78 | −$849,396.76 | 29,102 | Direct | |
| Oct 17, 2022 | Common Stock | SSaleDisposed | −358 | $739.50 | −$264,741 | 28,744 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 14, 2022 | Common Stock | MOption exerciseDisposed | −1,500 | $0.00 | $0 | 11,300 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.